๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for TP53 Gene Mutation

Immunohistochemical Algorithm for the Diagnosis and Classification of Hepatocellular Carcinomas With TERT, TP53 and CTNNB1 Mutation NCT06718153NA1 site๐Ÿ“ Bologna IRCCS Azienda Ospedaliero-Universitaria di Bologna ยท Tests: Immunohistochemistry and in situ hybridisation analysis Routine Shallow-coverage Whole Genome Sequencing Testing of Liquid-based Cervical Smears for the Early Diagnosis of Ovarian Cancer NCT07821879n/a1 site๐Ÿ“ Toulouse Institut Claudius Regaud A Phase 1b/2 Study of Ropeginterferon Alfa-2b Added to Azacitidine in MDS/AML With TP53 Mutations NCT07646821Phase 1, Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: ropeginterferon alfa- 2b, Azacitidine (AZA) MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies NCT05735717Phase 21 site๐Ÿ“ Minneapolis Masonic Cancer Center, University of Minnesota ยท Tests: Fludarabine, Busulfan, Melphalan, Rituximab, Levetiracetam Relapsed and Progressive Sonic Hedgehog Medulloblastoma With U1 Mutation Registry Study NCT07242963n/a2 sites๐Ÿ“ Houston๐Ÿ“ Houston Mohammad H. Abu Arja A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL NCT05197192Phase 330 sites๐Ÿ“ Bad Saarow๐Ÿ“ Berlin๐Ÿ“ Bremen German CLL Study Group ยท Tests: Obinutuzumab, Venetoclax, Acalabrutinib AZA Combined With RCHOP in P53-mutated DLBCL. NCT06158399Phase 21 site๐Ÿ“ Xiamen The First Affiliated Hospital of Xiamen University ยท Tests: Azacitidine in combination with R-CHOP NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations NCT06494540n/a30 sites๐Ÿ“ Bad Homburg๐Ÿ“ Berlin๐Ÿ“ Bremen AstraZeneca A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation NCT06778863Phase 121 sites๐Ÿ“ Scottsdale๐Ÿ“ Tucson๐Ÿ“ Los Angeles Clasp Therapeutics, Inc. ยท Tests: CLSP-1025 Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance NCT06043973Phase 31 site๐Ÿ“ Jinan Qianfoshan Hospital ยท Tests: almonertinib Interferon-ฮฑ for TP53 Myeloid Malignancy Post Allo-HSCT NCT06130579Phase 21 site๐Ÿ“ Beijing Peking University People's Hospital ยท Tests: IFN-ฮ‘ Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer NCT06413992Phase 21 site๐Ÿ“ Beijing Cancer Institute and Hospital, Chinese Academy of Medical Sโ€ฆ ยท Tests: Fluzoparib, Camrelizumab, paclitaxel (albumin bound), Carboplatin injection, Carboplatin Combination of CAR-DC Vaccine and ICIs in Malignant Tumors NCT05631886Phase 11 site๐Ÿ“ Beijing Chinese PLA General Hospital ยท Tests: TP53-EphA-2-CAR-DC, Abraxane, Cyclophosphamide, anti-PD-1 antibody, Anti-CTLA4 Monoclonal Antibody A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies. NCT07017816EARLY Phase 11 site๐Ÿ“ Washington D.C. Children's National Research Institute ยท Tests: SGT-53, hypofractionated radiotherapy with immunotherapy, Nivolumab Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naรฏve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib NCT06479135Phase 3215 sites๐Ÿ“ Birmingham๐Ÿ“ Gilbert๐Ÿ“ Phoenix Kartos Therapeutics, Inc. ยท Tests: Navtemadlin, Navtemadlin placebo, Ruxolitinib Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation NCT07499271Phase 21 site๐Ÿ“ Suzhou The First Affiliated Hospital of Soochow University ยท Tests: POLA-R-CHP, Orelabrutinib Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer NCT07198074Phase 3304 sites๐Ÿ“ Birmingham๐Ÿ“ Anchorage๐Ÿ“ Phoenix National Cancer Institute (NCI) ยท Tests: Bevacizumab, Biospecimen Collection, Carboplatin, Computed Tomography, Magnetic Resonance Imaging A Phase I First-in-Human Study of GenSci128 in Patients With Solid Tumors Harboring a TP53 Y220C Mutation NCT06908434Phase 11 site๐Ÿ“ Shanghai Changchun GeneScience Pharmaceutical Co., Ltd. ยท Tests: GenSci128 tablets Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery NCT02734537Phase 2679 sites๐Ÿ“ Birmingham๐Ÿ“ Anchorage๐Ÿ“ Anchorage ECOG-ACRIN Cancer Research Group ยท Tests: Cisplatin, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) NCT04585750Phase 1, Phase 276 sites๐Ÿ“ Irvine๐Ÿ“ La Jolla๐Ÿ“ Los Angeles PMV Pharmaceuticals, Inc ยท Tests: rezatapopt, pembrolizumab Li-Fraumeni Syndrome/TP53 Biobank NCT04367246n/a2 sites๐Ÿ“ Philadelphia๐Ÿ“ Phildelphia Abramson Cancer Center at Penn Medicine ยท Tests: No Intervention Oral-ATO for TP53-mutated Myeloid Malignancies NCT06778187Phase 21 site๐Ÿ“ Hong Kong The University of Hong Kong ยท Tests: Oral arsenic trioxide A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma NCT06136351Phase 21 site๐Ÿ“ Shanghai Ruijin Hospital ยท Tests: Zanubrutinib, Rituximab, Bendamustin Li-Fraumeni & TP53 (LiFT UP): Understanding and Progress NCT04541654n/a3 sites๐Ÿ“ Boston๐Ÿ“ Boston๐Ÿ“ Boston Dana-Farber Cancer Institute ยท Tests: Data and Specimen Collection Germline Genetic Testing of the TP53 Gene NCT07419893n/a1 site๐Ÿ“ Milan European Institute of Oncology Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML) NCT07008638Phase 1, Phase 21 site๐Ÿ“ Minneapolis Masonic Cancer Center, University of Minnesota ยท Tests: Bortezomib, CPX-351 A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation NCT07060989Phase 1, Phase 210 sites๐Ÿ“ New Haven๐Ÿ“ Houston๐Ÿ“ Fairfax Nutshell Therapeutics (Shanghai) Co., LTD. ยท Tests: NTS071 JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation NCT06386146Phase 1, Phase 215 sites๐Ÿ“ Denver๐Ÿ“ Lake Mary๐Ÿ“ St Louis Jacobio Pharmaceuticals Co., Ltd. ยท Tests: JAB-30355, JAB-30355 Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial) NCT06517511Phase 22 sites๐Ÿ“ Guangzhou๐Ÿ“ Shanghai Sun Yat-sen University ยท Tests: Selinexor Oral Tablet [Xpovio], R-CHOP Protocol A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation NCT05877599Phase 120 sites๐Ÿ“ Gilbert๐Ÿ“ Duarte๐Ÿ“ Los Angeles AstraZeneca ยท Tests: NT-175
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy